{"schema_version":"secwatch.filing_event.v1","accession":"0001326190-24-000053","form_type":"8-K","ticker":"ALT","cik":"0001326190","company_name":"Altimmune, Inc.","filed_at":"2024-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.116234+00:00","generated_at":"2026-05-29T04:38:05.804956+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Altimmune reports pemvidutide Phase 1b MASLD data: LFC reduced up to 68.5%","bullets":["Pemvidutide reduced liver fat content (LFC) by up to 68.5% from baseline over 12 weeks in 94 MASLD patients.","Total cholesterol decreased by up to 12.2% and triglycerides by up to 44.6% after 12 weeks of treatment.","Presented at AASLD The Liver Meeting from a 12-week Phase 1b trial in overweight/obese MASLD subjects.","Subjects received once-weekly subcutaneous pemvidutide (1.2mg, 1.8mg, 2.4mg) or placebo."],"urls":{"canonical":"https://secwatch.observer/filing/0001326190-24-000053","json":"https://secwatch.observer/filing/0001326190-24-000053.json","markdown":"https://secwatch.observer/filing/0001326190-24-000053.md","text":"https://secwatch.observer/filing/0001326190-24-000053.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326190/000132619024000053/0001326190-24-000053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326190/000132619024000053/alt-20241115x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T04:38:05.804956+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}